

## ANSWERING REVIEWERS:

Dear Editors and Reviewers,

We thank you for your review and opportunity to re-submit our manuscript entitled, **“Medical management of metabolic and cardiovascular complications after liver transplantation”**. We have revised the manuscript based on your comments. All changes are included in the manuscript with bolded and underlined text.

Kind regards,



Chiara Becchetti, MD  
On behalf of all co-authors

### Reviewer 1:

Comment to the authors: Dear Editor, I read this manuscript and I think that the paper is good and well written.

Thank you for your positive feedback.

### Reviewer 2:

Comment to the authors: This is a well written and easy to read manuscript which describes the potential reasons for long term graft loss after solid organ transplantation with special attention to metabolic syndrome. I have one comment on a sentence under the 'Dyslipidemia' section: It says that Ezetimibe may be considered in recipients who do not tolerate statins, although no efficacy data are available for this drug. However, there are studies related to this in the literature. I recommend the authors check those out before concluding. Almutairi F, Peterson TC, Molinari M, Walsh MJ, Alwayn I, Peltekian KM. Safety and effectiveness of ezetimibe in liver transplant recipients with hypercholesterolemia. Liver Transpl. 2009;15(5):504–508. doi:10.1002/lt.21710

Thank you for your comment and suggestion. We have reworded the sentence as follows: **Ezetimibe may be considered in recipients who do not tolerate statins, although the experience is scant [85].**

We have also included the reference that you suggested in the bibliography.